Innovative Protein Pharmaceutical Technology Platform

The pharmaceutical industry predominantly relies on a few key modified biopharmaceutical technologies, namely chemical modification, fusion protein creation, and amino acid sequence modification. UBI Pharma Inc., for instance, has chosen to employ the fusion protein technique in the development of two distinct platforms

polysaccharide protein fusion technology and
single-chain Fc (sFc) technology.

This approach stands apart from chemical modification as it centers on the inherent human body's natural sequence, eliminating concerns about polymer residue within the human body. Consequently, this method finds extensive application in the development of various novel biopharmaceuticals.

Polysaccharide Protein Fusion Platform

The polysaccharide protein fusion platform capitalizes on the presence of a higher number of sialic acids within proteins, leading to an extended half-life and a reduced rate of protein degradation in the body. This innovative approach aims to prolong the effectiveness of protein-based drugs.

Our Distinctive Edge and Expertise

	UBIP Polysaccharide Protein Fusion Platform	PEGylation
Action Principle	Utilizing fusion proteins to prolong the half-life of drugs within the body.	Modifying drugs by incorporating polyethylene glycol with functional groups to extend their half-life within the body.
Pros	Enhance water solubility of drugs. Extend the half-life. Enhance the structural stability of protein drugs High safety and non-immunogenicity. Ease of production and purification.	Enhance water solubility of drugs. Extend the half-life.
Cons	N/A	Increased User Risk：Chemically synthesized high-molecular-weight polymers are difficult to metabolize and eliminate from the body, leading to their continuous accumulation in the kidneys. Prolonged use poses a significant burden on the kidneys. Higher Production Costs：The production process that involves chemical synthesis of protein drugs incurs higher production costs. The structural uncertainty of protein drugs created through this method is greater than that of simple proteins. This results in a greater allocation of time and resources for purification, quality control, and quality assurance.

Single Chain Fc (sFc) Technology Platform

The single chain Fc (sFc) technology platform leverages the prolonged circulation of antibodies within the body. It connects biopharmaceuticals to the single chain Fc segment of the antibody, thereby extending their half-life in the body.

Our Distinctive Edge and Expertise

	UBIP	Amgen	Biogen
Feature	One sFc fuses with 1 drug	One Fc fuses with 2 drugs	One Fc fuses with 1 drug
Pros	Prolonged half-life. Lack of structural barriers. Ease of production and purification.	Prolonged half-life.	Prolonged half-life. Reduction of structural barriers.
Cons	N/A	Impact on Efficacy: The close spatial proximity of two protein drugs can lead to steric hindrance, affecting their activity.	Higher Production Costs: Difficulties in manufacturing and purification contribute to elevated production costs.